At ReNeuron, we’re advancing precision medicine with CustomEX™ – our customisable exosome platform built from engineered stem cells. Designed for targeted delivery, CustomEX™ brings new potential to therapeutic innovation.
ReNeuron is a biotechnology company harnessing the natural biology of exosomes to develop next-generation drug delivery systems. With deep roots in stem cell research, we are uniquely positioned to advance exosome technologies into clinically meaningful solutions.
Our multidisciplinary team brings together leading expertise in exosome biology, stem cell research, targeted drug delivery, and translational science. Together, we’re unlocking the full therapeutic potential of exosomes.
BSc CDir
Chairman
PhD
Managing Director & CSO
MSc MBA
Non-Executive Director
PhD
Head of Research
BSc, ACA
Finance Director
Founded on a legacy of pioneering stem cell science and clinical translation, ReNeuron has been at the forefront of cell-based technologies for more than 20 years. Today, our transition to exosome-focused therapeutics builds on this heritage – leveraging our CustomEX™ platform to support in-house R&D and strategic partnerships.
Discover how our cutting-edge exosome platform is built to meet the demands of next-generation treatments, with precision, consistency, and targeted impact.
At the core of ReNeuron’s scientific platform is CustomEX™ — a biologically driven, scalable exosome delivery system designed to meet the demands of next-generation therapeutics. Built on a foundation of proprietary, conditionally immortalised stem cell lines and iPSCs, CustomEX™ enables the consistent production of high-quality exosomes with well-characterised biological properties and innate tissue-targeting capabilities.
Unlike systems that rely on synthetic modifications or post-production engineering, our tailored catalogue strategy offers a diverse library of exosome types, each derived from distinct, conditionally immortalised stem cells and with specific tissue tropisms. By leveraging the inherent biological properties of exosomes and their producer cells, CustomEX™ allows for precise selection of the optimal exosome for a given therapeutic payload and indication – streamlining development and enhancing delivery accuracy.
Four Proprietary Neural Stem Cell Lines
Three Proprietary Stem Cell Lines
CI-iPSC
Any Stem Cell
Four Proprietary Neural Stem Cell Lines
Three Proprietary Stem Cell Lines
CI-iPSC
Any Stem Cell
At ReNeuron, we take a biologically driven approach to precision drug delivery. We match the right exosome to the right tissue, enabling more effective intracellular delivery and the ability to traverse complex biological barriers – including access to traditionally hard-to-reach sites like the central nervous system (CNS).
Our proprietary CustomEX™ platform produces exosomes from a unique catalogue of conditionally immortalised stem cell lines, enabling the delivery of a wide range of therapeutic payloads — from small molecules to RNA and proteins — directly to the tissues that matter most. By combining the precision, scalability, and versatility of CustomEX™, we’re redefining what’s possible in targeted therapeutics.
Exit from Administration as a Going Concern
Re-launch as a Private company focused on its stem cell line development expertise
Uploaded 24 Mar 2025
Learn moreSee how our technology is advancing both exosome and cell-based research
Publication
Neural stem cell–derived extracellular vesicles purified by monolith chromatography retain stimulatory effect in in vitro scratch assay – Cytotherapy (2025)
Uploaded 21 Dec 2024
Learn morePublication
Investigating heparin affinity chromatography for extracellular vesicle purification and fractionation – ScienceDirect (2022)
Uploaded 12 Jul 2025
Learn morePublication
Exosomes from neuronal stem cells may protect the heart from ischaemia/reperfusion injury via JAK1/2 and gp130 – Journal of Cellular and Molecular Medicine (2021)
Uploaded 12 Jul 2025
Learn morePublication
High content, quantitative AFM analysis of the scalable biomechanical properties of extracellular vesicles – Nanoscale (2021)
Uploaded 12 Jul 2025
Learn morePublication
Investigation of Content, Stoichiometry and Transfer of miRNA from Human Neural Stem Cell Line Derived Exosomes – PLOS One (2016)
Uploaded 12 Jul 2025
Learn moreStem cell line resource
ReNcell CX and VM – Immortalised human neural stem cell lines developed by ReNeuron, available to purchase.
Uploaded 12 Jul 2025
Learn moreStem cell line resource
A summary of ReNeuron’s conditionally immortalised stem cells
Uploaded 12 Jul 2025
Learn moreStem cell line resource
Publications of interest – Explore how ReNeuron’s technology is being used in the scientific community
Uploaded 12 Jul 2025
Learn more
Sitemap
Contact
© designed by Carr Kamasa Design 2025